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Abstract
Among persons who inject drugs (IDU), illicit drug use often occurs in hospitals and contributes to
patient expulsion and/or high rates of leaving against medical advice (AMA) when withdrawal is
inadequately managed. Resultant disruptions in medical care may increase the likelihood of several
harms including drug resistance to antibiotics as well as costly readmissions and increased patient
morbidity. In this context, there remains a clear need for the evaluation of harm reduction
strategies versus abstinence-based strategies with respect to addressing ongoing issues related to
substance use among addicted hospitalized patients. While hospitalization can be used to stabilize
addicted patients as they recover from their acute illness and help them to achieve abstinence,
patients unable to maintain abstinence should not be penalized for failing to do so at the expense
of their health. This article describes harm reduction activities within hospitals and areas for future
investigation.
Introduction
Soft-tissue infections and other injection-related infec-
tions are among the main contributors to health service
use among people who inject drugs (IDU) [1-6]. In many
settings, the two most common reasons for emergency
department (ED) visits relate to soft-tissue infections, and
problems related directly to drug use (e.g., over-
dose)[1,2,4,6]. Not-surprisingly, many IDU use EDs as a
regular point of care; IDU are generally less likely to use
outpatient services compared to non-IDU[4] and gener-
ally face poor access to prevention programs and addic-
tion treatment services [7-9].
As a result, IDU often present to EDs later in the course of
their illness, and this in turn increases the likelihood for
hospital admission [2,4,5]. Drug-related infections are
often painful and may progress to more serious life- and
limb-threatening conditions [10]. More complicated
infections such as endocarditis require extended periods
of treatment with intravenous antibiotics and thus may
require even longer hospital stays.
However, IDU are more likely than other patients to dis-
charge from hospitals against medical advice (AMA)
[11,12]. A 2002 study noted that IDU were over four times
more likely to leave AMA compared to non-IDU [12] and
leaving AMA is a strong predictor for frequent readmis-
sion [11-13]; Moreover, repeated admissions for chronic
medical problems are generally more costly for total days
of stay than single, cost-intensive stays [13].
In addition to the high costs associated with increased
health utilization, these findings also suggest that patients
are not fully recovering from their illness the first time
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they are treated. Incomplete therapy or treatment failure
may also increase the likelihood for drug resistance to
antibiotics [11,13,14]. As such, uncovering why IDU are
more likely to leave AMA is a necessary first step in order
to improve health outcomes, although incidentally this
may also decrease the high costs associated with elevated
rates of health service utilization.
Discussion
Harm Reduction
While an abstinence-based approach to drug use generally
requires that complete cessation from all non-prescribed
drugs is a pre-requisite for effective addiction treatment
[15], harm reduction emphasizes that efforts to improve
health and social outcomes should begin with 'where a
person is at' in terms of their drug use [16]. Strategies need
to be maximized, both in terms of types of services offered
and where they operate. Furthermore, abstinence-based
programs are generally considered high-threshold refer-
ring to the eligibility criteria for participation in such pro-
grams and the state of 'readiness' individuals need to be in
prior to entry [16,17]. Low threshold services, including
needle exchange programmes (NEPs), have minimal
requirements for involvement and put IDU in contact
with a continuum of care even when they may not be
ready to engage in abstinence-based treatment [18]. Harm
reduction involves a continuous spectrum of strategies,
from the promotion of safer and managed drug use to
complete abstinence [15]. Harm reduction advocates and
guidelines [19] suggest that strategies to reduce the high
risk of disease transmission should be culturally relevant
and implemented within multiple contexts, including
health care facilities such as hospitals [18]. Indeed, evi-
dence suggests that active drug use does occur in hospitals
and is associated with leaving AMA [12,20].
In terms of specific strategies, methadone maintenance
treatment (MMT) has been associated with reductions in
the need for hospitalization and generally results in
improvements in health care access [2,20]. NEPs work to
reduce disease transmission by lowering the rate of
syringe sharing and the number and length of time used
syringes are in circulation [7,21-24]. Supervised Injecting
Facilities (SIFs) have also demonstrated success in the
reduction of HIV risk and other harms among IDU. At
North America's first SIF, IDU are provided with sterile
syringes, primary care services, and referral to addiction
treatment, as well as to emergency care [25]. SIF use has
been associated with increases in safer injecting practices
[26,27], more rapid entry into detox programs [27] and
generally increased uptake of addiction treatment [9].
Gaps in Service Delivery
While achieving abstinence from illicit drug use is ideal,
for many individuals, this may be difficult, particularly
without adequate support. Health care for drug users
often follows psychiatric models of care that involve the
use of contracts developed for addiction management.
When this contract is breached (i.e., drug use continues),
the patient may be discharged back into the community
with cessation of care [28]. Such approaches have poten-
tially significant ethical implications as they may impede
appropriate care for drug users [29].
Negative experiences with the medical establishment may
also impede health care delivery for IDU [30]. Leaving
hospital AMA predisposes individuals not only to poor
health outcomes due to inadequate treatment but also to
major disruptions in the patient-provider relationship
[20]. Recently, our local teaching hospital generated con-
troversy when a strict illicit drug use policy that essentially
allows for 'evictions' of drug users who are unable to
maintain abstinence while in hospital was proposed.
While this policy is currently under review, similar guide-
lines are in place in most hospitals in North America. The
fact that active drug use occurs in hospitals and is one rea-
son why many IDU leave AMA raises the question that if
active drug use was accommodated rather than banned in
hospitals, rates of leaving AMA would decline. While
incorporating harm reduction in hospitals to deal with
addicted patients raises a host of ethical and well as staff
and patient safety issues, such an approach has the poten-
tial to result not only in better health outcomes but
reduced readmissions.
Incorporation of harm reduction programs
Indeed, harm reduction programs have already shown
success when integrated with medical care. Increased inte-
gration of low- and medium-threshold harm reduction
strategies with primary and acute care has been associated
with increasing the proportion of IDU who have regular
health care [28].
For instance, the Dr. Peter Centre in Vancouver which pro-
vides low-threshold access to care for people living with
HIV/AIDS including a high proportion of IDU offers one
example where harm reduction has been successfully inte-
grated with a medical facility. Many conventional barriers
have been removed at the Centre including the need to
remain drug-free. MMT and the distribution of condoms
and clean needles are also provided [30]. An interdiscipli-
nary team embraces harm reduction through the promo-
tion of self-care and autonomy and in the spring of 2002,
the nurses implemented a pilot project involving the
supervision of injections in the nursing treatment room.
An opiate-overdose protocol was also developed and
illicit drugs including crack cocaine can be smoked in a
designated area on the premises. By May 2003, staff had
noted a reduced incidence of soft-tissue infections associ-
ated with use of the injecting room [31].Harm Reduction Journal 2009, 6:19 http://www.harmreductionjournal.com/content/6/1/19
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At the Dr. Peter Centre, participants are able to build trust-
ing relationships with healthcare staff; such a facility
offers an important solution to increase acceptability of
care while reducing stigma among IDU. Importantly, the
continuity of care from both nurses and doctors has
shown to be an effective means for reducing injection-
related complications and the need for hospital admis-
sion [28,30].
Specific harm reduction strategies including drug substitu-
tion for opioid addiction, smoking rooms for tobacco and
illicit drugs, and protocols to help manage drug with-
drawal symptoms have already demonstrated success in
their integration into health care facilities and should con-
tinue to be fully implemented into hospitals. For exam-
ple, in-patient MMT has been associated with a reduced
likelihood of leaving AMA which may reflect adequate
and appropriate management for opioid withdrawal [20].
Certifying a greater number of physicians who are able to
prescribe buprenorphine has also already been shown to
result in a reduced number of hospitalizations and risk of
complications [32]. Providing patients presenting with
obvious physical withdrawal with additional doses of opi-
ates or short courses of benzodiazepines has been associ-
ated with reductions in agitation and early discharge [20].
Other strategies, while proven effective in community set-
tings, still require further study given their potential role
in reducing harm among hospital-admitted IDU. Super-
vised injecting areas and NEPs, in particular, could be
evaluated as services that could be made accessible for
hospital patients, particularly those with longer stays or in
wards that are designated for dealing with addicted indi-
viduals. Ideally, the availability of these services would
also help to facilitate positive patient-provider relation-
ships.
Conclusion
Active drug use occurs in hospitals and contributes to high
rates of leaving AMA among IDU. As discussed, if active
drug use was accommodated through more of a harm
reduction approach rather than banned in hospitals, rates
of leaving AMA would likely decline. Regardless, there
remains the need for evaluation of several novel harm
reduction interventions versus abstinence-based strategies
with respect to addressing ongoing issues related to stig-
matization and elevated rates of leaving AMA. This may
lend itself to a randomized trial or perhaps it is better
examined via observational data where the objective
would be to evaluate whether the incorporation of a dif-
ferent harm reduction programs (e.g., safer injecting
spaces) in hospitals results in reduced rates of patients
leaving AMA and overall improvements in health out-
comes for IDU who are able to access these services versus
those who do not. Given the contact that many IDU have
with EDs, it seems fitting that harm reduction programs
should continue to expand to the hospital setting, partic-
ularly when the number of IDU being treated is high. The
goal is to use hospitalization to stabilize addicted patients
as they recover from their acute illness and see if they can
be helped to achieve abstinence. However, patients una-
ble to maintain abstinence should not be penalized for
failing to do so at the expense of their health.
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